罗氏或将为Ariosa出价6.25亿美元

  罗氏公司本周透露其将为无创产前诊断公司Ariosa支付高达6.25亿美元的收购金额。

  罗氏在其财务报告中称，这项交易包含4亿美元的现金支付以及多达2.25亿美元的或有对价安排。罗氏也透露将为其在12月收购的生物信息公司Bina科技支付高达1.21亿美元的收购金额。

  1月28日，罗氏报告称其在2014年的诊断收入同比增长了3个百分点，其中分子诊断的收入提高了6%。虽然在2014年罗氏测序业务并无突破增长，但MDx业务增长了8%。（转化医学网360zhyx.com）

  以上为转化医学网原创翻译整理。如需转载，请联系 info@360zhyx.com。

原文：

Roche Discloses Potential $625M Price Tag for Ariosa
NEW YORK (GenomeWeb) – Roche disclosed this week that it is paying up to $625 million for non-invasive prenatal testing firm Ariosa Diagnostics.

The terms of the deal include a cash payment of $400 million and up to $225 million from a contingent consideration arrangement, Roche said in its financial report. It also disclosed that it is paying up to $121 million for informatics company Bina Technologies, which it acquired in December.

On Wednesday, Roche reported a 3 percent increase year over year in its full-year 2014 diagnostic revenues, including a 6 percent increase in its molecular diagnostics revenues. The company did not break out its next-generation sequencing sales, but said that excluding those sales, the MDx business was up 8 percent year over year in 2014.